Creative Planning Avadel Pharmaceuticals PLC Transaction History

Creative Planning

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$12.55 - $17.22 $79,805 - $109,501	-6,359 Reduced 35.72%	11,443 $193,000
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $16,156 - $24,452	-1,676 Reduced 8.6%	17,802 $251,000
Q3 2023 Nov 16, 2023	BUY	$10.3 - $15.99 $4,511 - $7,003	438 Added 2.3%	19,478 $200,000
Q2 2023 Jul 21, 2023	BUY	$8.48 - $16.48 $4,952 - $9,624	584 Added 3.16%	19,040 $313,000
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $5,442 - $8,447	849 Added 4.82%	18,456 $169,000
Q4 2022 Feb 10, 2023	BUY	$5.02 - $10.0 $2,725 - $5,430	543 Added 3.18%	17,607 $126,000
Q3 2022 Nov 03, 2022	BUY	$2.57 - $7.31 $3,281 - $9,334	1,277 Added 8.09%	17,064 $85,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $2,228 - $14,476	2,083 Added 15.2%	15,787 $39,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $12,847 - $19,506	2,353 Added 20.73%	13,704 $94,000
Q4 2021 Feb 11, 2022	BUY	$7.34 - $11.18 $83,316 - $126,904	11,351 New	11,351 $92,000
Q2 2021 Aug 04, 2021	SELL	$6.73 - $9.05 $105,661 - $142,085	-15,700 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$5.03 - $7.95 $78,971 - $124,815	15,700 New	15,700 $105,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.